Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
NCT07227896
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson's Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AbbVie
- Last updated on ClinicalTrials.gov
- November 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190 · Boca Raton, FL
- University of South Florida- Neuroscience Institute /ID# 278562 · Tampa, FL
North Carolina · 1
- Novant Health /ID# 278567 · Charlotte, NC
Texas · 1
- Texas Movement Disorder Specialists /ID# 278565 · Georgetown, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.